An approach to characterising the cohesive behaviour of powders using a flow titration aerosolisation based methodology

被引:26
作者
Behara, Srinivas Ravindra Babu [1 ]
Larson, Ian [1 ]
Kippax, Paul [2 ]
Morton, David A. V. [1 ]
Stewart, Peter [1 ]
机构
[1] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
[2] Malvern Instruments, Malvern WR14 1XZ, Worcs, England
关键词
Aerosols; Agglomeration; Dispersion; Pharmaceutical; Cohesive powders; Non-linear regression modelling; INTERACTIVE MIXTURES; CASCADE IMPACTOR; INHALATION FLOW; PERFORMANCE; PARTICLES; ADHESION; DISSOLUTION; FORMULATION; BREAKAGE; INHALERS;
D O I
10.1016/j.ces.2010.12.044
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
The purpose of this study was to characterise the cohesive behaviour of powders by measuring aerosolisation at a sequence of different flow rates, i.e. flow titration. Salbutamol sulphate and Lactohale 300 were model cohesive materials. Laser diffraction particle sizing of the aerosolised plume provided in-situ, real time particle size distributions of the aerosolised powder dispersed at increasing flow rates, from 30 to 180 L min(-1). Relative de-agglomeration was determined from the cumulative particle size of the aerosolised powder less than 5.4 mu m compared with the full availability of particles in that size range. Relative de-agglomeration-flow rate profiles were modelled using a non-linearleast squares regression to fit an empirical 3-parameter sigmoidal equation; the parameters of the sigmoid were estimated from the data. Relative de-agglomeration-flow rate titration profiles and their estimated parameters were obtained to define the different de-agglomeration mechanisms of the two cohesive powders. Salbutamol sulphate showed a maximum percent de-agglomeration of 54.9%, compared with Lactohale 300 which was only 29.5%. Lactohale 300 gave 50% of its maximum de-agglomeration at a flow rate of 48.0 L min(-1) while the equivalent for Salbutamol sulphate was 113.8 L min(-1). Salbutamol sulphate and Lactohale 300 demonstrated different patterns of dispersion in relation to de-agglomeration mechanism. This approach to characterising the aerosolisation processes has significant application in designing formulation and processing strategies for pharmaceutical inhalation drug delivery. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1640 / 1648
页数:9
相关论文
共 36 条
[1]  
ADI H, 2006, THESIS MONASH U
[2]   Micro-particle corrugation, adhesion and inhalation aerosol efficiency [J].
Adi, Santoso ;
Adi, Handoko ;
Tang, Patricia ;
Traini, Daniela ;
Chan, Hak-Kim ;
Young, Paul M. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 35 (1-2) :12-18
[3]   Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? [J].
Al-Showair, Raid A. M. ;
Tarsin, Walid Y. ;
Assi, Khaled H. ;
Pearson, Stantey B. ;
Chrystyn, Henry .
RESPIRATORY MEDICINE, 2007, 101 (11) :2395-2401
[4]   Modelling the dissolution of diazepam in lactose interactive mixtures [J].
Alway, B ;
Sangchantra, R ;
Stewart, PJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 130 (02) :213-224
[5]  
[Anonymous], 1966, Applied regression analysis
[6]  
[Anonymous], THEORY PRACTICE IND
[7]   Use of solid corrugated particles to enhance powder aerosol performance [J].
Chew, NYK ;
Chan, HK .
PHARMACEUTICAL RESEARCH, 2001, 18 (11) :1570-1577
[8]   THE RELATIONSHIP BETWEEN POWDER INHALER RESISTANCE AND PEAK INSPIRATORY CONDITIONS IN HEALTHY-VOLUNTEERS - IMPLICATIONS FOR IN-VITRO TESTING [J].
CLARK, AR ;
HOLLINGWORTH, AM .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1993, 6 (02) :99-110
[9]   Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses [J].
Coates, MS ;
Chan, HK ;
Fletcher, DF ;
Raper, JA .
PHARMACEUTICAL RESEARCH, 2005, 22 (09) :1445-1453
[10]   Air classifier technology (ACT) in dry powder inhalation Part II. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation [J].
de Boer, AH ;
Hagedoorn, P ;
Gjaltema, D ;
Goede, J ;
Kussendrager, KD ;
Frijlink, HW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) :201-216